To assess the impact of GSK3β activity in leukemia cells, Zhou et al. exposed T-ALL JURKAT cells, CML K562 cells, and myeloma RPMI-8226 cells to the GSK3β kinase inhibitors LiCl and SB216763. This evidence concerns the gene GSK3B and plasma cell myeloma.